• Home

Home > Medical Reference > Patient Education

• Highlights
• Introduction
• Symptoms
• Causes
• Risk Factors
• Complications
• Diagnosis
• Prognosis
• Treatment
• Home Management
• Treatment to Achieve Remission
• Treatment During Remission
• Treatment After Relapse
• Resources
• References

Acute lymphocytic leukemia

Description

An in-depth report on the causes, diagnosis, treatment, and prevention of leukemia.

Alternative Names

Acute lymphoblastic (or lymphocytic) leukemia

Treatment to Achieve Remission

The aim of induction therapy, the first treatment phase, is to reduce the number of leukemia cells to undetectable levels. The general guidelines for induction therapy are as follows:

• Patients are given intensive chemotherapy that uses powerful multi-drug regimens. (Infants require special regimens not discussed here.)
• For both children and adults, some of these therapies are administered orally, others intravenously.
• Hospitalization is usually necessary at some point to help prevent infection and to administer blood products. However, much of this therapy can be given on an outpatient basis.
• After the first cycle of induction, bone marrow tests are done to determine if the patient is in remission.
• Another bone marrow test is sometimes done about a week later to confirm the first results.
• A bone marrow transplant is considered for patients who do not respond at all to induction treatment.

Drugs Used for Induction Chemotherapy

Drugs Used for Standard or Low-Risk Patients. A three-drug regimen is typically used for standard or low-risk patients. (A fourth drug, such as cyclophosphamide, may be added for adult patients.) Examples of drugs used in regimens for children include:

• Vincristine
• Corticosteroids (prednisone or dexamethasone) -- a 2003 study reported better survival rates with dexamethasone compared to prednisone.
• Asparaginase -- several forms are available, including L-asparaginase (Elspar) and pegaspargase (Oncaspar). In 2006, the FDA approved the use of pegaspargase in place of L-asparaginase for treating newly diagnosed ALL in children and adults. (Pegaspargase had previously been approved only for patients who were allergic to L-asparaginase.) With pegaspargase, patients will need to receive only 3 injections over a 20-week period instead of the 21 injections required for L-asparaginase.

When this regimen is used together with CNS prophylaxis, remission rates of greater than 95% have been achieved in children. In a 2001 study, researchers reported that the most effective regimen for many children uses dexamethasone after the first month with a longer duration for asparaginase (30 rather than the standard 20 weeks.

Drugs Used for High-Risk Children. A four- or five-drug regimen is used for many high-risk children. An example of a four-drug regimen would be vincristine, prednisone/dexamethasone, plus asparaginase, and an anthracycline (such as doxorubicin, daunorubicin, or epirubicin).

Drugs Used for Specific High-Risk Adults. Adult patients have a poorer outlook than children, and researchers are looking for more effective chemotherapy regimens. For example, cyclophosphamide-based regimens are used in adult patients with certain types of ALL. In a 2005 study, patients treated with an investigational regimen of cytabarine and high-dose mitoxantrone experienced a much higher rate of remission and survival than patients treated with the standard L-20 chemotherapy regimen of vincristine, prednisone, cyclophosphamide, and doxorubicin. Patients with the Philadelphia chromosome also benefited from the investigational treatment.

Preventing Central Nervous System Disease (CNS Prophylaxis)

CNS prophylaxis is critical for preventing disease that has spread to the brain, spine, and testes (called sanctuary disease sites). Although only 3% of children with ALL have evidence of leukemia in the central nervous system (CNS) at the time of diagnosis, leukemia will spread to this region in between 50 - 70% of children without preventive (prophylactic) treatment. The brain is one of the first sites for relapsing leukemia.

CNS prophylaxis is usually:

• Administered together with induction therapy before moving to consolidation, the next standard treatment phase, particularly if there are any leukemic cells detected in the spinal fluid.
• Given through intrathecal chemotherapy, in which a drug is injected directly into the spinal fluid. The drugs used are either methotrexate alone or a combination of methotrexate, hydrocortisone, and cytarabine. (Induction chemotherapy does not penetrate the blood-brain barrier sufficiently to destroy leukemic cells in the brain.)
• In some cases, methotrexate, with or without other drugs, is given as systemic (widespread) therapy at the same time as intrathecal chemotherapy. The addition of this treatment is effective in preventing relapse in the central nervous system and can substitute for radiation to the skull.

Cranial Radiation Therapy. Some high-risk children also receive radiation to the skull (cranial irradiation), radiation to the spine, or both at the same time. This combination can be very toxic and can cause later learning problems. It is generally used only in children who have evidence of the disease in the central nervous system at the time of diagnosis. Later complications can include learning and neurologic problems. Using lower-dose units of radiation, however, is proving to be effective and to significantly reduce the risk for mental impairment. Cranial radiation is also associated with later risk factors for heart disease and stroke.

A 2003 study reported the long-term effects of cranial or craniospinal radiation therapy during initial treatment for ALL. Among patients who achieved at least 10 years of event-free survival, those who received radiation therapy had a significantly higher risk of a second neoplasm, a slightly elevated mortality rate, and higher unemployment rate than patients who did not receive radiation therapy.

Indications for Remission after Induction Treatment Survival in acute leukemia depends on complete remission. Although not always clear-cut, remission is indicated by the following: All signs and symptoms of leukemia disappear. There are no abnormal cells in the blood, bone marrow, and cerebrospinal fluid. The percentage of blast cells in the bone marrow is less than 5%. Blood platelet count returns to normal. Induction can produce extremely rapid results, and the faster the time to remission the better the outlook: A complete remission usually occurs within the first 4 weeks. Patients who show low disease levels within 7 - 14 days have an excellent outlook, particularly if they have favorable genetic factors, and may need less-intensive treatments afterward. Patients with high disease levels at 14 days or who require more than 4 weeks to achieve remission are at higher risk for relapse and most likely need more aggressive treatment. According to a 2002 study, the timing of blood platelet recovery may be a simple and important way of predicting remission. The quicker the recovery, the more likely the patient will achieve a complete remission.

Side Effects and Complications

Side effects and complications of any chemotherapeutic regimen are common, are more severe with higher doses, and increase over the course of treatment. Toxicities can be reduced without loss of cancer-killing effects in some cases by administering the drugs for shorter duration.

Common Side Effects . Common side effects include:

• Nausea and vomiting. Drugs known as serotonin antagonists, such as ondansetron (Zofran) or granisteron (Kyril), can relieve these side effects in nearly all patients given moderate drugs and most patients who take more powerful drugs. In one study, nearly all patients who took a combination of dexamethasone (a steroid) in combination with ondansetron within 24 hours of chemotherapy experienced either a significant or complete reduction in nausea and vomiting.
• Diarrhea
• Hair loss
• Weight loss
• Depression

These side effects are nearly always temporary. Most patients are able to continue with normal activities for all but perhaps 1 or 2 days a month.

Serious Side Effects. Serious side effects can also occur and may vary depending on the specific drugs used. Infection from suppression of the immune system or from severe drops in white blood cells is a common and serious side effect. Patients should make all efforts to prevent them. The patient at high risk for infection may require very potent antibiotics and antifungal medications as well as granulocyte colony-stimulating factors or G-CSF (lenograstim, filgrastim) to stimulate the growth of infection-fighting white blood cells.

Other side effects include:

• Liver and kidney damage
• Abnormal blood clotting
• Allergic reaction
• Low blood sugar (hypoglycemia) -- a rare complication in young, thin children who are taking purine analogues such as mercaptopurine and thioguanine
• Shrinking of adrenal glands in children who take short-term, high-dose corticosteroids such as prednisolone

Long-Term Complications.

• Fatigue is very common after chemotherapy and can be significant and long-lasting.
• Combinations of intrathecal chemotherapy plus brain radiation in children can cause some serious complications, including seizures and problems in learning and concentration. Methotrexate is particularly toxic. (The effects of intrathecal chemotherapy alone on mental functioning, however, did not seem significant.) Seizures can often be treated successfully with anti-epilepsy medications.
• Late puberty. The effects of treatment in the brain can affect regions that regulate reproductive hormones, which may affect fertility later on.
• Bone loss can occur after chemotherapy, particularly with corticosteroids and after bone marrow transplantation. Drugs are available, particularly bisphosphonates, which may help reduce this risk.
• Pancreatic beta-cell damage. A 2004 study reported that children who have been off treatment for at least 1 year have a higher risk of impaired insulin response. This suggests that chemotherapy-induced beta cell damage persists after therapy has been stopped.
• Anthracyclines (doxorubicin, daunorubicin, epirubicin) have been associated with later development of heart failure. Of some encouragement, a 2000 study reported that low doses used for many ALL children may not pose a high risk to the heart. Some anthracyclines (DaunoXome, Myocet, Doxil) now come in tiny protective capsules that may reduce toxic effects.
• Mood disorders. According to a 2003 study, CNS radiation and MTX therapy were associated with an increased risk of mood disturbances (such as depression) among adult survivors of childhood ALL. This suggests that patients undergoing CNS radiation and MTX therapy may benefit from psychosocial support.

• Review Date: 1/16/2007
• Reviewed By: Harvey Simon, MD, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.